Stage II HR-Positive Invasive Ductal Carcinoma: Doreen's Patient Story

Patient Info: Doreen, Female | Stage II

Biomarkers: ER-positive; PR-positive; HER2-positive

As of June 2026, Doreen had completed TCHP chemotherapy with a complete response before surgery and had undergone lumpectomy and radiation for Stage IIA triple-positive breast cancer.

The Patient StoryRead more →

Stage II HR-Positive Invasive Ductal Carcinoma: Callie's Survivor Story

Patient Info: Callie, Female, Under 40 | Stage II

Biomarkers: ER-positive

As of June 2026, Callie described survivorship after mastectomy, ACT chemotherapy, reconstruction, and hysterectomy for Stage IIB ER-positive IDC, with all cancer-directed treatment completed by the end of 2019.

The Patient StoryRead more →

Stage II BRCA1 Breast Cancer: Joy's Survivor Story

Patient Info: Joy R., Female | Stage II

Biomarkers: BRCA1 mutation

As of June 2026, Joy had no evidence of disease after chemotherapy, double mastectomy, and hysterectomy for Stage II breast cancer with a BRCA1 mutation, and had moved from 3-month to 6-month oncology monitoring.

The Patient StoryRead more →

Stage II Invasive Ductal Carcinoma: Monica's Survivor Story

Patient Info: Monica, Female, Under 40 | Stage II

As of June 2026, Monica described survivorship after treatment for Stage IIB breast cancer and a separate undifferentiated pleomorphic sarcoma, with lasting neuropathy, bone pain, reconstruction complications, and grief around fertility.

The Patient StoryRead more →

Stage III Breast Cancer: Andrea's Survivor Story

Patient Info: Andrea, Female, Under 40 | Stage III

Completed chemotherapy, mastectomy/reconstruction, and radiation for Stage IIB-to-Stage III breast cancer diagnosed during pregnancy, and later described survivorship, parenting, fatigue, relationship strain, and recovery after treatment.

The Patient StoryRead more →

Stage II HR-Positive Breast Cancer: Rach's Patient Story

Patient Info: Rach D., Female, Under 40 | Stage II

Biomarkers: ER-positive; PR-positive; HER2-positive

As of June 2026, Rach described Stage II triple-positive breast cancer treated with fertility preservation, 6 rounds of neoadjuvant TCHP including Herceptin, Zoladex ovarian suppression, and double mastectomy with reconstruction.

The Patient StoryRead more →

Stage IV Triple-Negative Breast Cancer: Janice's Patient Story

Patient Info: Janice, Female, Under 40 | Stage IV

Biomarkers: ER-negative; PR-negative; HER2-negative

Metastatic Site: Other sites not specified

Living with incurable Stage IV triple-negative breast cancer while advocating for dose adjustments, symptom management, and balancing quality of life with survival.

The Patient StoryRead more →

BRCA2 Breast Cancer: Erika's Patient Story

Patient Info: Erika, Female, Under 40

Biomarkers: BRCA2 mutation

As of June 2026, Erika had no cancer diagnosis after a BRCA2-positive result and preventive double mastectomy with implant reconstruction, with ongoing hereditary-risk surveillance.

The Patient StoryRead more →

Stage IV Triple-Negative Breast Cancer: Erin's Patient Story

Patient Info: Erin, Female | Stage IV

Biomarkers: ER-negative; PR-negative; HER2-negative; later tumor responded to androgen signaling

Metastatic Site: Lung; brain

As of June 2026, Erin was living with metastatic triple-negative breast cancer involving lung and brain, with tumors shrinking on ongoing Gemzar plus carboplatin chemotherapy every 2 weeks.

The Patient StoryRead more →

Stage III HER2-Positive Breast Cancer: Genoa's Survivor Story

Patient Info: Genoa M., Female | Stage III

Biomarkers: HER2-positive; ER-positive

As of June 2026, Genoa had completed treatment for Stage III HER2-positive, ER-positive breast cancer with neoadjuvant Taxotere/carboplatin/trastuzumab, lumpectomy, and radiation, and was focused on survivorship and rebuilding life after treatment.

The Patient StoryRead more →

Stage I HR-Positive Invasive Ductal Carcinoma: Amelia's Patient Story

Patient Info: Amelia, Female, 40s | Stage I

Biomarkers: ER-positive; PR-positive; HER2-negative; BRCA negative; Oncotype DX score 22

As of June 2026, Amelia had no evidence of disease after lumpectomy, bilateral mastectomy, TC chemotherapy, and reconstruction, and she remained on tamoxifen.

The Patient StoryRead more →

Stage II HR-Positive Invasive Ductal Carcinoma: Cat's Survivor Story

Patient Info: Cat, Female | Stage II

Biomarkers: ER-positive; Oncotype recurrence risk discussed

As of June 2026, Cat described being cancer-free after bilateral mastectomy, 4 months of chemotherapy, reconstruction, and a period on tamoxifen for ER-positive Stage IIB breast cancer.

The Patient StoryRead more →

Stage I Invasive Ductal Carcinoma: Rachel's Patient Story

Patient Info: Rachel, Female | Stage I

Biomarkers: Genetic testing inconclusive; receptor status not reported

As of June 2026, Rachel had completed double mastectomy and chemotherapy for Stage IB breast cancer and remained on planned 10-year tamoxifen therapy, with ongoing joint/muscle pain, weight gain, and survivorship effects.

The Patient StoryRead more →

Stage IV HER2-Positive Invasive Ductal Carcinoma: Renee's Patient Story

Patient Info: Renee N., Female | Stage IV

Biomarkers: HER2-positive

Metastatic Site: Brain

As of June 2026, Renee’s public story described living with metastatic HER2-positive breast cancer as a chronic illness, after brain radiation and while on Kadcyla every 3 weeks with stable scans reported in December 2019 and early March 2020.

The Patient StoryRead more →

Stage II Invasive Ductal Carcinoma: Margaret's Survivor Story

Patient Info: Margaret, Female | Stage II

Biomarkers: Onco-typing score 18; hormone-responsive tumor described; exact receptor status not reported

As of June 2026, Margaret’s story described completed surgery, chemotherapy, radiation, and later reconstruction for Stage II IDC/DCIS breast cancer, with survivorship focused on recovery, neuropathy, and integrative support rather than an explicit NED claim.

The Patient StoryRead more →

Metastatic triple-negative breast cancer with orbital and bone metastases responding to nab-paclitaxel plus everolimus

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: Primary breast cancer was ER-low, PR/HER2 negative. Orbital metastasis was triple-negative with AKT1 exon 4 mutation.

Metastatic Site: right orbit/orbital mass; bone

At 6-month follow-up, systemic disease was stable, ocular symptoms had significantly improved, orbital metastases were stable on MRI, and the response was described as RECIST partial response/progression-free interval while treatment continued.

PubMed CentralRead more →

Amy’s Stage 4 Hormone-Positive Lobular Breast Cancer Story

Patient Info: Amy, Female | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-negative

Metastatic Site: Spine; pelvis

Amy was living with de novo stage 4 lobular breast cancer involving the spine and pelvis and remained active in rural-patient advocacy.

Lobular Breast Cancer AllianceRead more →

Breast cancer treatment during pregnancy followed by postpartum targeted therapy

Patient Info: Anonymized, Female, Under 40 | Stage IV

She achieved a near-complete response after 4 cycles of docetaxel and then continued systemic treatment after delivery.

PubMed CentralRead more →

Stage IIB triple-negative metaplastic breast cancer with early metastatic recurrence: durable response to pembrolizumab-based therapy

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Triple-negative metaplastic breast cancer with PD-L1 CPS 83.2, BRCA1/2 negative

Metastatic Site: lung, sternum

As of May 2026, she had more than 30 months of disease control after pembrolizumab-based therapy for early recurrent metastatic metaplastic breast cancer, with only mild residual sternal uptake and no disease progression.

PubMed CentralRead more →

My Metastatic Breast Cancer Spread To My BRAIN!

Patient Info: Anonymized, Female, 40s | Stage IV

Metastatic Site: brain

As of May 2026, the patient was living with metastatic breast cancer involving the brain, receiving 2 brain-directed chemotherapy infusions every 3 weeks, and describing the disease as chronic rather than a death sentence.

YouTube — The Patient StoryRead more →

Localized malignant phyllodes tumor of the breast: re-excision, radiation, and 24-month NED

Patient Info: Anonymized, Female, 40s

Biomarkers: Ki-67 20%; CD99-positive; Bcl2-positive; CD34-positive

Follow-up at 3, 6, 12, 18, and 24 months, including imaging and tumor-marker blood tests, showed no evidence of disease.

PubMed CentralRead more →

Stage IV Breast Cancer: Gynna's Patient Story

Patient Info: Gynna, Female, Under 40 | Stage IV

Metastatic Site: Bone

As of May 2026, Gynna was living with Stage IV metastatic breast cancer in the bones; after progression in June 2025, she had a partial response by December 2025 and continued indefinite treatment.

I Lost My Wife To Metastatic Breast Cancer at 29 Years Old

Patient Info: Samantha, Female, Under 40 | Stage IV

Metastatic Site: rib/bone; lymph nodes; brain; liver

Samantha died from metastatic breast cancer in early January 2026 at age 29 after brain and liver progression, heart failure, and tumor lysis syndrome during her final hospitalization.

The Patient StoryRead more →

Stage IV BRCA Breast Cancer: Maralee's Survivor Story

Patient Info: Maralee, Female, Under 40 | Stage IV

Biomarkers: BRCA mutation

Metastatic Site: Brain

As of May 2026, Maralee had no evidence of active disease after prior Stage IV breast cancer with brain metastasis, had stopped the PARP inhibitor after 2 years, remained without brain recurrence long enough to pursue pregnancy, and gave birth to a second daughter.

Cleveland ClinicRead more →